Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Congress Report ESMO 2017

Congress Report ESMO 2017 special issue ASCO 2017 ASCO 2017 Table of Contents S50 Preface S50 EGFR-targeted treatments: insights from the adjuvant to the resistant setting S53 New standards of care for ALK-positive disease S55 Reducing the danger that arises from the CNS as a site of progression S58 Diagnostics of EGFR-mutant disease: bio- markers with significant clinical implications S60 Established targeted agents taking root in S66 Interview: Lung cancer in China: hurdles and the HER2-positive setting progress S62 Further defining the optimal use of immune S66 Anti-angiogenic and immunotherapeutic checkpoint inhibitors approaches in mesothelioma S65 Real-world utility of ctDNA NGS to identify S69 Enhancing the profile of KRAS-mutant lung matched targeted therapy cancer Editorial Board: Alex A. Adjei, MD, PhD, FACP, Roswell Park, Cancer Institute, New York, USA Maria Rosario Garcia Campelo, MD, Lung Cancer and Thoracic Tumors, University Hospital Quirón A Coruña, La Coruña, Spain Federico Cappuzzo, MD, Medical Oncology Department, Ospedale Civile di Livorno, Livorno, Italy Wolfgang Hilbe, MD, Departement of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria Maximilian Hochmair, MD, 1. Interne Lungenabteilung, Otto-Wagner-Spital, Vienna, Austria Massimo Di Maio, MD, National Institute of Tumor Research and Therapy, Foundation G. Pascale, Napoli, Italy Filippo de Marinis, MD, PhD, Director http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Congress Report ESMO 2017

memo - Magazine of European Medical Oncology , Volume 10 (3) – Aug 7, 2017

Loading next page...
 
/lp/springer-journals/congress-report-esmo-2017-fofJbtDO0G
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag GmbH Austria
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0347-z
Publisher site
See Article on Publisher Site

Abstract

special issue ASCO 2017 ASCO 2017 Table of Contents S50 Preface S50 EGFR-targeted treatments: insights from the adjuvant to the resistant setting S53 New standards of care for ALK-positive disease S55 Reducing the danger that arises from the CNS as a site of progression S58 Diagnostics of EGFR-mutant disease: bio- markers with significant clinical implications S60 Established targeted agents taking root in S66 Interview: Lung cancer in China: hurdles and the HER2-positive setting progress S62 Further defining the optimal use of immune S66 Anti-angiogenic and immunotherapeutic checkpoint inhibitors approaches in mesothelioma S65 Real-world utility of ctDNA NGS to identify S69 Enhancing the profile of KRAS-mutant lung matched targeted therapy cancer Editorial Board: Alex A. Adjei, MD, PhD, FACP, Roswell Park, Cancer Institute, New York, USA Maria Rosario Garcia Campelo, MD, Lung Cancer and Thoracic Tumors, University Hospital Quirón A Coruña, La Coruña, Spain Federico Cappuzzo, MD, Medical Oncology Department, Ospedale Civile di Livorno, Livorno, Italy Wolfgang Hilbe, MD, Departement of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria Maximilian Hochmair, MD, 1. Interne Lungenabteilung, Otto-Wagner-Spital, Vienna, Austria Massimo Di Maio, MD, National Institute of Tumor Research and Therapy, Foundation G. Pascale, Napoli, Italy Filippo de Marinis, MD, PhD, Director

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Aug 7, 2017

There are no references for this article.